GlyCare® 2FL/DFL
GlyCare® 2 fucosyllactose & difucosyllactose
GlyCare® 2FL/DFL will be available as a mix of 2'FL and DFL in a ratio close to the composition naturally found in breast milk1.
2'FL (2'fucosyllactose) is the most abundant fucosylated Human Milk Oligosaccharide (HMO) in human milk at ~2g/L. Clinical research describes that 2'FL is positively supporting the health of infants.
DFL (DiFucosyllactose or Lactodifucotetraose, LDFT) is a highly abundant fucosylated HMO in human milk. Emerging preclinical data suggests a potential role for DFL in gut health.
Gut health and microbiota
Preclinical studies suggest DFL may reduce the risk of pathogenic bacteria adhering to the intestinal cell wall2,3,4. Additional preclinical data suggests DFL may also support gut health by selectively supporting the growth of beneficial bacteria such as bifidobacteria5,6.
2FL/DFL has been approved as a Novel Food in Europe and regulatory filings have been made in the US. Preparation is on the way for other major markets.
GlyCare® 2FL/DFL is available commercially.
References
1. Thurl S, Munzert M, Boehm G, Matthews C, Stahl B. Systematic review of the concentrations of oligosaccharides in human milk. Nutr Rev. 2017;75(11):920-933. doi:10.1093/nutrit/nux044
2. Coppa, G. V., Zampini, L., Galeazzi, T., Facinelli, B., Ferrante, L., Capretti, R., & Orazio, G. (2006). Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris. Pediatric Research, 59(3), 377–382. https://doi.org/10.1203/01.pdr.0000200805.45593.17
3. Cravioto, A., Tello, A., Villafan, H., Ruiz, J., Del Vedovo, S., & Neeser, J. R. (1991). Inhibition of localized adhesion of enteropathogenic Escherichia coli to HEp-2 cells by immunoglobulin and oligosaccharide fractions of human colostrum and breast milk. Journal of Infectious Diseases, 163(6), 1247–1255. https://doi.org/10.1093/infdis/163.6.1247
4. Craft, K. M., & Townsend, S. D. (2019). Mother Knows Best: Deciphering the Antibacterial Properties of Human Milk Oligosaccharides. Accounts of Chemical Research, 52(3), 760–768. https://doi.org/10.1021/acs.accounts.8b00630
5. Asakuma, S., Hatakeyama, E., Urashima, T., Yoshida, E., Katayama, T., Yamamoto, K., Kumagai, H., Ashida, H., Hirose, J., and Kitaoka, M. (2011). Physiology of consumption of human milk oligosaccha- rides by infant gut-associated bifidobacteria. Journal of Biological Chemistry, 286(40):34583–34592.
6. Yu, Z. T., Chen, C., Kling, D. E., Liu, B., McCoy, J. M., Merighi, M., … Newburg, D. S. (2013). The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology, 23(2), 169–177. https://doi.org/10.1093/glycob/cws138
HMO health benefits & solutions
Human milk oligosaccharides may support a number of health benefits such as immunity and gut health in early life.
Related articles
-
It takes guts and science: Unlock the latest research behind human milk oligosaccharides (HMOs) for human health
-
Supporting the infant microbiome: Exploring the science of synergistic synbiotics at ESPGHAN 2024
-
Explore the science behind synbiotic solutions combining HMOs and probiotics plus their benefits for infant health and development.
How can we help you?
-
New product concept
Got a notion for your next project or breakthrough innovation? Let’s put our heads together.
-
Sample request
Don’t just take our word for it. Discover how our solutions can support your product development journey.
-
-
Quick links
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.